🔴 Anixa Biosciences is trading 5% down; no clear company-specific catalyst identified

Anixa Biosciences is trading 5.28% down at $2.69, with no clear company-specific catalyst identified.

• On October 13, the company announced that its ovarian cancer CAR-T therapy inventor will give a keynote at a November conference. The release reported no trial results or other material event and did not link the announcement to the share-price move.
• Biotech shares faced broader pressure, with XBI down 2.01% while broader market indices were nearly flat. Sector weakness may be relevant context, but evidence does not establish it as the direct cause.